Advances in Immunotherapy of Non-small Cell Lung Cancer
XU Shihao
QIAN Jun
Abstract：Non-small cell lung cancer(NSCLC)is one of the malignancies with high morbidity and mortality.Despite the continuous optimization of chemotherapy and molecularly targeted therapies,the 5-year survival rate for patients with ad-vanced NSCLC remains low.Currently,immune checkpoint inhibitor therapy has made a major breakthrough in the anti-tumor field,especially programmed death receptor-1/programmed death ligand-1 inhibitor therapy,which is considered to be the ma-instay of treatment for NSCLC.This article reviews the current research status and related issues of immunotherapy for NSCLC.
Keywords：Lung tumorCancernon-small cell lungImmunotherapyTargeted therapyProgrammed death receptor-1Programmed death ligand-1Immune checkpoint inhibitorsReview
Publication Date：2024-04-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 284-287 )